双歧杆菌四联活菌胶囊治疗肠易激综合征的临床效果

Clinical study on Bifidobacterium Tetravaccine Capsules for irritable bowel syndrome

目的观察双歧杆菌四联活菌胶囊治疗肠易激综合征（IBS）的临床效果。方法将2015年1~4月就诊于河北北方学院附属第二医院的60例确诊为肠易激综合征的患者依据随机数字法分为观察组和对照组,每组各30例;观察组给予双歧杆菌四联活菌胶囊治疗,对照组给予马来酸曲美布汀分散片治疗,疗程均为4周。观察两组患者服药后的临床疗效,统计治疗有效率。结果观察组患者21例患者治疗有效,对照组患者25例患者治疗有效,两组疗效比较差异有统计学意义（χ2=1.491,P〈0.05）。结论双歧杆菌四联活菌胶囊与目前治疗IBS效果确切的马来酸曲美布汀分散片效果相当,可用于治疗IBS。

Objective To investigate the effect of Bifidobacterium Tetravaccine Capsules on irritable bowel syndrome（IBS）. Methods 60 patients with diarrhea-predominant irritable bowel syndrome in the Second Affiliated Hosipital to Hebei North University from January 2015 to April 2015 were divided into observation group and control group according to random number table method, with 30 patients in each group. Patients in observation group were given Bifidobacterium Tetravaccine Capsules, patients in control group were given Trimebutine Maleate Dispersible Tablets. The patients in each group were all treated with drug for four weeks. The effect was observed, and the effective rate was censused. Results There were 21 effectively treated patients in observation group, 25 effectively treated patients in control group, with statistical significance（χ2=1.491, P 0.05）. Conclusion The clinical efficacy of Bifidobacterium Tetravaccine Capsules and Trimebutine Maleate Dispersible Tablets are both good, and the clinical efficacy of Trimebutine Maleate Dispersible Tablets is sure. So Bifidobacterium Tetravaccine Capsules can be used in treating irritable bowel syndrome.